Consequently, following with the world's first selective PI3Kδ inhibitor CAL-101 was approved by the FDA for the treatment of FL, CLL and SLL in 2014 [315] [NCT01282424, NCT02136511], the PI3K/AKT inhibitors have shown remarkable activity in an increasing subset of patients with NHL [316] (Tables 2, 3). This evidence concerns the gene PIK3CB and non-Hodgkin lymphoma.